Carbinoxamine

Carbinoxamine
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sree Teja Yelamanchili, MBBS [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Carbinoxamine is {{{aOrAn}}} {{{drugClass}}} that is FDA approved for the treatment of {{{indication}}}. Common adverse reactions include {{{adverseReactions}}}.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

There is limited information regarding Carbinoxamine FDA-Labeled Indications and Dosage (Adult) in the drug label.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Carbinoxamine in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Carbinoxamine in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Carbinoxamine FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Carbinoxamine in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Carbinoxamine in pediatric patients.

Contraindications

There is limited information regarding Carbinoxamine Contraindications in the drug label.

Warnings

There is limited information regarding Carbinoxamine Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Carbinoxamine Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Carbinoxamine Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Carbinoxamine Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Carbinoxamine in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Carbinoxamine in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Carbinoxamine during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Carbinoxamine in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Carbinoxamine in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Carbinoxamine in geriatric settings.

Gender

There is no FDA guidance on the use of Carbinoxamine with respect to specific gender populations.

Race

There is no FDA guidance on the use of Carbinoxamine with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Carbinoxamine in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Carbinoxamine in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Carbinoxamine in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Carbinoxamine in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Carbinoxamine Administration in the drug label.

Monitoring

There is limited information regarding Carbinoxamine Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Carbinoxamine and IV administrations.

Overdosage

There is limited information regarding Carbinoxamine overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Carbinoxamine Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Carbinoxamine Mechanism of Action in the drug label.

Structure

There is limited information regarding Carbinoxamine Structure in the drug label.

Pharmacodynamics

There is limited information regarding Carbinoxamine Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Carbinoxamine Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Carbinoxamine Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Carbinoxamine Clinical Studies in the drug label.

How Supplied

There is limited information regarding Carbinoxamine How Supplied in the drug label.

Storage

There is limited information regarding Carbinoxamine Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Carbinoxamine |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Carbinoxamine |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Carbinoxamine Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Carbinoxamine interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Carbinoxamine Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Carbinoxamine Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Carbinoxamine

File:Carbinoxamine.svg
Clinical data
Pregnancy category	C
Routes of administration	Oral: 4 mg tablet or 4 mg/5 mL liquid
ATC code	R06AA08 (WHO)
Legal status
Legal status	4 mg is FDA approved
Pharmacokinetic data
Elimination half-life	10 to 20 hours
Identifiers
IUPAC name 2-[(4-chlorophenyl)-pyridin-2-yl-methoxy]-N,N- dimethyl-ethanamine
CAS Number	486-16-8
PubChem CID	2564
DrugBank	APRD00765
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C16H19ClN2O
Molar mass	290.788 g/mol

Carbinoxamine is an H1 class antihistamine. It was first launched in the United States by the McNeil Corporation under the brand name Clistin. It is now available under the brand name Palgic as 4 mg tablets or 4 mg/5 mL liquid. It is FDA approved (specifically at the 4 mg dose/strength) for hay fever (a.k.a. allergic rhinitis, SAR and PAR); vasomotor rhinitis; mild urticaria; angioedema, dermatographism and allergic conjunctivitis.

Carbinoxamine liquid is popular with children because the taste is very mild and easily swallowed. Palgic liquid is clear and has a bubble gum flavor.

In June, 2006 the FDA announced that more than 120 branded pharmacy products containing carbinoxamine were being illegally marketed, and demanded they be removed from the marketplace. This action was precipitated by twenty-one reported deaths in children under the age of two who had been administered carbinoxamine-containing products. Despite the fact that the drug had not been studied in this age group, a multitude of OTC preparations containing carbinoxamine were being marketed for infants and toddlers. At present, all carbinoxamine-containing formulations are approved only for adults or children ages 3 or older. [3]

External links

• Carbinoxamine